BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...unit kicked off the buying spree in November 2018 when it acquired another Versant-backed NLRP3 play, Jecure Therapeutics Inc....
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...also eligible for up to $1.3 billion in milestones (see “Novartis Buying IFM Inflammasome” ). Jecure Therapeutics Inc....
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

...in innate immune assets. Versant was the founding and sole investor in NLRP3 inflammasome company Jecure Therapeutics Inc....
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...for solid tumors. The third acquisition happened last year, when Roche’s Genentech Inc. unit bought Jecure Therapeutics Inc....
...indications. Novartis hasn’t disclosed the inflammatory indication for its Phase I compound. However, NodThera and Jecure Therapeutics Inc....
...Squibb Co. (NYSE:BMY), New York, N.Y. IFM Therapeutics LLC, Boston, Mass. Inflazome Ltd., Dublin, Ireland Jecure Therapeutics Inc....
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...program, IFM-2427, that started Phase I trials in March, and two others in preclinical development. Jecure Therapeutics Inc....
...of interest to us,” said Versant Ventures’s Graham Walmsley. Versant was a founding investor in Jecure Therapeutics Inc....
BioCentury | Feb 16, 2019
Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

...the gut, and the company told BioCentury last year it has NASH on its radar. Jecure Therapeutics Inc....
BioCentury | Nov 30, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Genentech Inc. is acquiring Jecure Therapeutics Inc. (San Diego, Calif.), giving it a preclinical program targeting NLR family...
...Roche (SIX:ROG; OTCQX:RHHBY). Jecure Therapeutics Inc., San Diego, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Inflammation Paul Bonanos Genentech Inc. Jecure Therapeutics Inc. Roche NLR...
BioCentury | Nov 27, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Genentech Inc. is acquiring Jecure Therapeutics Inc. (San Diego, Calif.), giving it a preclinical program targeting NLR family...
...which also includes Feldstein and Stafford. Genentech is a unit of Roche (SIX:ROG; OTCQX:RHHBY). Paul Bonanos Genentech Inc. Jecure Therapeutics Inc. NLR...
BioCentury | Jun 29, 2018
Financial News

NASH play Akero emerges from stealth with $65M

...is expected in the field," Walmsley added. Versant's portfolio includes NASH and liver fibrosis company Jecure Therapeutics Inc....
...Tree's Aaron Kantoff and venBio's Aaron Royston. Akero Therapeutics Inc., Cambridge, Mass. Jennie Walters GS-0976, ndi-010976 Amgen Inc. Atlas Venture Jecure Therapeutics Inc. Versant...
BioCentury | Jun 25, 2018
Financial News

NASH play Akero emerges from stealth with $65M

...is expected in the field," Walmsley added. Versant's portfolio includes NASH and liver fibrosis company Jecure Therapeutics Inc....
Items per page:
1 - 10 of 16
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...unit kicked off the buying spree in November 2018 when it acquired another Versant-backed NLRP3 play, Jecure Therapeutics Inc....
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...also eligible for up to $1.3 billion in milestones (see “Novartis Buying IFM Inflammasome” ). Jecure Therapeutics Inc....
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

...in innate immune assets. Versant was the founding and sole investor in NLRP3 inflammasome company Jecure Therapeutics Inc....
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...for solid tumors. The third acquisition happened last year, when Roche’s Genentech Inc. unit bought Jecure Therapeutics Inc....
...indications. Novartis hasn’t disclosed the inflammatory indication for its Phase I compound. However, NodThera and Jecure Therapeutics Inc....
...Squibb Co. (NYSE:BMY), New York, N.Y. IFM Therapeutics LLC, Boston, Mass. Inflazome Ltd., Dublin, Ireland Jecure Therapeutics Inc....
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...program, IFM-2427, that started Phase I trials in March, and two others in preclinical development. Jecure Therapeutics Inc....
...of interest to us,” said Versant Ventures’s Graham Walmsley. Versant was a founding investor in Jecure Therapeutics Inc....
BioCentury | Feb 16, 2019
Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

...the gut, and the company told BioCentury last year it has NASH on its radar. Jecure Therapeutics Inc....
BioCentury | Nov 30, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Genentech Inc. is acquiring Jecure Therapeutics Inc. (San Diego, Calif.), giving it a preclinical program targeting NLR family...
...Roche (SIX:ROG; OTCQX:RHHBY). Jecure Therapeutics Inc., San Diego, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Inflammation Paul Bonanos Genentech Inc. Jecure Therapeutics Inc. Roche NLR...
BioCentury | Nov 27, 2018
Company News

Genentech acquiring Versant-backed NASH play Jecure

...Genentech Inc. is acquiring Jecure Therapeutics Inc. (San Diego, Calif.), giving it a preclinical program targeting NLR family...
...which also includes Feldstein and Stafford. Genentech is a unit of Roche (SIX:ROG; OTCQX:RHHBY). Paul Bonanos Genentech Inc. Jecure Therapeutics Inc. NLR...
BioCentury | Jun 29, 2018
Financial News

NASH play Akero emerges from stealth with $65M

...is expected in the field," Walmsley added. Versant's portfolio includes NASH and liver fibrosis company Jecure Therapeutics Inc....
...Tree's Aaron Kantoff and venBio's Aaron Royston. Akero Therapeutics Inc., Cambridge, Mass. Jennie Walters GS-0976, ndi-010976 Amgen Inc. Atlas Venture Jecure Therapeutics Inc. Versant...
BioCentury | Jun 25, 2018
Financial News

NASH play Akero emerges from stealth with $65M

...is expected in the field," Walmsley added. Versant's portfolio includes NASH and liver fibrosis company Jecure Therapeutics Inc....
Items per page:
1 - 10 of 16